Interview with Willem Dekker , Regional Director, Nycomed Australia
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Address: 2-4 Lyonpark Road,MACQUARIE PARK NSW 2113,Australia
Tel: 61 (02) 9859 6900
Web: http://www.takedaaustralia.com.au/au/
Building valued partnerships with the medical professionals who prescribe and recommend our products is both Nycomed Australia’s greatest challenge and our greatest reward. These aspirations as well as our commitment to provide medicines that offer real promise to patients, drives us to seek innovative and efficient ways of presenting our products to the Australian market.
Through a commitment to the ethical and professional delivery of quality medical education, Nycomed Australia is continually building valued relationships with the medical community. This is achieved by the creation of focused disease state education programs, and the facilitation of knowledge sharing between thought leaders and primary care practitioners. While Nycomed Australia always strive to keep Somac® (pantoprazole) and Alvesco ® (ciclesonide) at the ‘top of the mind’ of Australian prescribers, activities are often unrelated to their products and instead focus on topics of clearly identified educational needs within the areas of Gastroenterology and Respiratory Medicine.
In addition to building relationships with individual healthcare professionals, Nycomed Australia seeks to develop productive partnerships with the peak bodies that share our therapeutic focus. For example, The Gastroenterology Society of Australia guides us in the field of gastroenterology. In the area of respiratory medicine, Nycomed Australia has developed positive relationships with both the National Asthma Council and the Australian Lung Foundation. Nycomed Australia is also excited by the prospect of pioneering new relationships with peak bodies in emerging areas of therapeutic interest.
As a member of Medicines Australia, Nycomed Australia is devoted to strengthening the pharmaceutical industry’s position as a partner in quality healthcare delivery. This is achieved through the ethical promotion of our products and our support of the Medicines Australia code of conduct. Nycomed and its people are proud of their contribution to the Australian healthcare environment and seek to ensure that their organisation acts as a trusted pharmaceutical partner.
Every day across Australia, our highly trained industry-accredited representatives bring life to our products and services. They are the face of Nycomed Australia.
Nycomed Australia’s professional team is committed to our vision to become the preferred pharmaceutical company by being responsive, reliable and by understanding customer needs.
Gastroenterology and Respiratory Medicine
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Would you please introduce The Pharmacy Guild to our readers, giving an insight in its function and its membership? We are the premium body representing community pharmacies in Australia, about…
Earlier this year the company set a crucial step in its internationalization strategy with the acquisition of Ascent. Would you outline the significance of the acquisition within Watson’s global expansion…
We last met you in 2008 as Chair of the Pharmaceuticals Industry Council (PIC), which set itself the goal of doubling the levels of exports, R&D investment, manufacturing, value-added activities,…
Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike…
You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your…
You returned to Australia a year ago after spending eight years in Europe with the company. In your view, what were the key changes in the Australian market? Looking at…
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine,…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique, as it is a…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
See our Cookie Privacy Policy Here
